The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials
Abstract
OBJECTIVES: This study aims to systematically identify and summarize the effects of antifungal prophylaxis in non-neutropenic critically ill adult patients on all-cause mortality and the incidence of invasive fungal infections. METHODS: Systematic review and meta-analysis of randomized controlled trials in all languages comparing the prophylactic use of any antifungal agent or regimen with placebo, no antifungal or another antifungal agent or regimen in non-neutropenic critically ill adult patients. We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 3, 2005), MEDLINE (1966 to 2 September 2005) and EMBASE (1980 to week 36, 2005). We also hand-searched reference lists, abstracts of conference proceedings and scientific meetings (1998-2004) and contacted authors of included studies and pharmaceutical manufacturers. The primary outcomes assessed were all-cause mortality and proven invasive fungal infections. Two reviewers independently applied selection criteria, performed quality assessment and extracted data using an intention-to-treat approach. Data were synthesized using the random effects model and expressed as relative risk with 95% confidence intervals. RESULTS: Twelve unique trials (eight comparing fluconazole and four ketoconazole with no antifungal or a non-absorbable agent) involving 1606 randomized patients were included. For both outcomes of total mortality and invasive fungal infections, almost all trials of fluconazole and ketoconazole separately showed a non-significant risk reduction with prophylaxis. When combined, fluconazole/ketoconazole reduced total mortality by one-quarter (relative risk 0.76, 95% confidence interval 0.59-0.97) and invasive fungal infections by about one-half (relative risk 0.46, 95% confidence interval 0.31-0.68). No significant increase in the incidence of infection or colonization with the azole-resistant fungal pathogens Candida glabrata or Candida krusei was demonstrated, although the confidence intervals of the summary effect measures were wide. Adverse effects requiring treatment discontinuation were not more common amongst patients receiving prophylaxis. Results across all trials were homogeneous despite considerable heterogeneity in clinical and methodological characteristics. CONCLUSIONS: Prophylaxis with fluconazole or ketoconazole in critically ill patients reduces invasive fungal infections by one-half and total mortality by one-quarter. Although no significant increase in azole-resistant Candida species associated with prophylaxis was demonstrated, trials were not powered to exclude such an effect. In patients at increased risk of invasive fungal infections, antifungal prophylaxis with fluconazole should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · cited 1×
“Funguria in the absence of a complicated urinary tract infection, and mucocutaneous fungal infections, including fungal oesophagitis, were classified as superficial, rather than invasive, infections.(22,25) Secondary outcomes were suspected invasive fungal infections (systemic antifungal therapy without criteria for p…”
BackgroundCandida Colonization and Subsequent Infections in Critically III Surgical Patients
Pittet, D., Monod, M., Suter, P. M., Frenk, E., & Auckenthaler, R. (1994) · Annals of Surgery · doi:10.1097/00000658-199412000-00008 · Cited by 798
Epidemiology of nosocomial fungal infections
Fridkin, S. K., & Jarvis, W. R. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.499 · Cited by 782
Rangel‐Frausto, M. S., Wiblin, T., Blumberg, H. M., Saiman, L., Patterson, J., Rinaldi, M., Pfaller, M., Edwards, Jr., Jarvis, W., Dawson, J., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/520194 · Cited by 430
Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients
Eggimann, P., Francioli, P., Bille, J., Schneider, R., Wu, M.-M., Chapuis, G., Chiolero, R., Pannatier, A., Schilling, J., Geroulanos, S., et al. (1999) · Critical Care Medicine · doi:10.1097/00003246-199906000-00019 · Cited by 414
The Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Rentz, A. M., Halpern, M. T., & Bowden, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514955 · Cited by 310
Sandven, P., Qvist, H., Skovlund, E., & Giercksky, K. E. (2002) · Critical Care Medicine · doi:10.1097/00003246-200203000-00008 · Cited by 201
Paphitou, N. I., Ostrosky-Zeichner, L., & Rex, J. H. (2005) · Medical Mycology · doi:10.1080/13693780410001731619 · Cited by 179
Prophylactic antifungal therapy in the intensive care unit
Weinstein, R. A., Rex, J. H., & Sobel, J. D. (2001) · Clinical Infectious Diseases · doi:10.1086/319763 · Cited by 155
Candida infections: outcome and attributable ICU costs in critically ill patients
Pelz, R. K., Lipsett, P. A., Swoboda, S. M., Diener-West, M., Powe, N. R., Brower, R. G., Perl, T. M., Hammond, J. M., & Hendrix, C. W. (2000) · Journal of Intensive Care Medicine · doi:10.1046/j.1525-1489.2000.00255.x · Cited by 45
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Clancy, C. J., & Nguyen, M. H. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit006 · Cited by 688
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
A Multicenter, Randomized Trial of Prophylactic Fluconazole in Preterm Neonates
Manzoni, P., Stolfi, I., Pugni, L., Decembrino, L., Magnani, C., Vetrano, G., Tridapalli, E., Corona, G., Giovannozzi, C., Farina, D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065733 · Cited by 356
Patients at High Risk of Invasive Fungal Infections: When and How to Treat
Rüping, M. J. G. T., Vehreschild, J. J., & Cornely, O. A. (2008) · Drugs · doi:10.2165/00003495-200868140-00002 · Cited by 253
Effect of antifungal therapy timing on mortality in cancer patients with candidemia
Taur, Y., Cohen, N., Dubnow, S., Paskovaty, A., & Seo, S. K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00945-09 · Cited by 127
The current treatment landscape: Candidiasis
Bassetti, M., Peghin, M., & Timsit, J.-F. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw392 · Cited by 99
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients
Cortegiani, A., Russotto, V., Maggiore, A., Attanasio, M., Naro, A. R., Raineri, S. M., & Giarratano, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004920.pub3 · Cited by 91
Occurrence, presentation and treatment of candidemia
Mikulska, M., Del Bono, V., Ratto, S., & Viscoli, C. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.52 · Cited by 71
Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
Lepak, A., & Andes, D. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.001 · Cited by 62
Prophylaxis, empirical and preemptive treatment of invasive candidiasis
Playford, E. G., Lipman, J., & Sorrell, T. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e10e8 · Cited by 41
Self-citation
Metadata
- Authors
- Playford, E. G., Webster, A. C., Sorrell, T. C., & Craig, J. C.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-02-03
- Volume
- 57
- Issue
- 4
- Pages
- 628-638
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2107803653
- Cited by
- 159
- References
- 10
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.